Duloxetine: A review of its use in the treatment of major depressive disorder

CNS Drugs

Volumn 21, Issue 7, 2007, Pages 581-609

  Frampton, James E ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; ASPARTATE AMINOTRANSFERASE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; DULOXETINE; ESCITALOPRAM; FLUOXETINE; HISTAMINE H1 RECEPTOR; LORAZEPAM; MILNACIPRAN; MOXIFLOXACIN; MUSCARINIC RECEPTOR; NORADRENALIN TRANSPORTER; OPIATE RECEPTOR; PAROXETINE; PLACEBO; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TEMAZEPAM; THEOPHYLLINE; UNINDEXED DRUG; VENLAFAXINE; ZOPICLONE;

AGE DISTRIBUTION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; APPETITE; AREA UNDER THE CURVE; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BACKACHE; BINDING AFFINITY; BODY WEIGHT; CLINICAL TRIAL; COGNITION; CONSTIPATION; CONTROLLED RELEASE FORMULATION; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE EXACERBATION; DIZZINESS; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG TOLERABILITY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; EMOTIONAL DISORDER; FATIGUE; FLU LIKE SYNDROME; HAMILTON SCALE; HEART RATE; HUMAN; HYPERTENSION; HYPOMANIA; HYPONATREMIA; INFLUENZA; INSOMNIA; IRRITABILITY; LABORATORY TEST; LIVER CIRRHOSIS; LIVER METABOLISM; MAJOR DEPRESSION; MALE SEXUAL DYSFUNCTION; MANIA; NAUSEA; NIGHTMARE; PAIN; PARESTHESIA; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; RHINOPHARYNGITIS; SEX DIFFERENCE; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SIDE EFFECT; SOMNOLENCE; STEADY STATE; SUICIDAL BEHAVIOR; SUICIDAL IDEATION; SUICIDE; SWEATING; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; VISUAL ANALOG SCALE; VOMITING; WEIGHT GAIN; XEROSTOMIA; YAWNING;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; HUMANS; RANDOMIZED CONTROLLED TRIALS; THIOPHENES;

EID: 34347238257     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-200721070-00004     Document Type: Review

References (124)

1. Bymaster FP, Lee TC, Knadler MP, et al. The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression. Curr Pharm Des 2005; 11 (12): 1475-93
2. Cymbalta 30mg hard gastro-resistant capsules, Cymbalta 60mg hard gastro-resistant capsules: summary of product characteristics. Basingstoke: Eli Lilly and Company Limited, 2006 Dec 17
3. Cymbalta® (duloxetine hydrochloride) delayed-release capsules prescribing information. Indianapolis (IN): Eli Lilly and Company, 2007
4. Yentreve 20mg and 40mg hard gastro-resistant capsules: summary of product characteristics. Eli Lilly and Company Limited, 2007 Jan 17
5. Stahl SM, Grady MM, Moret C, et al. SNRIs: their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants. CNS Spectr 2005 Aug; 10 (9): 732-47
6. Bauer M, Moller HJ, Schneider E. Duloxetine: a new selective and dual-acting antidepressant. Expert Opin Pharmacother 2006 Mar; 7 (4): 421-7
7. Mann JJ. The medical management of depression. N Engl J Med 2005 Oct 27; 353 (17): 1819-34
8. Tran PV, Bymaster FP, McNamara RK, et al. Dual monoamine modulation for improved treatment of major depressive disorder. J Clin Psychopharmacol 2003 Feb; 23 (1): 78-86
9. Briley M. Specific serotonin and noradrenaline reuptake inhibitors (SNRIs): a review of their pharmacology, clinical efficacy and tolerability. Hum Psychopharmacol 1998; 13 (2): 99-111
10. Wong DT, Bymaster FP, Mayle DA, et al. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacology 1993 Jan; 8 (1): 23-33
11. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001 Dec; 25 (6): 871-80
12. Karpa KD, Cavanaugh JE, Lakoski JM. Duloxetine pharmacology: profile of a dual monoamine modulator. CNS Drug Rev 2002 Winter; 8 (4): 361-76
13. Reneric JP, Lucki I. Antidepressant behavioral effects by dual inhibition of monoamine reuptake in the rat forced swimming test. Psychopharmacology (Berl) 1998 Mar; 136 (2): 190-7
14. Katoh A, Eigyo M, Ishibashi C, et al. Behavioral and electroencephalographic properties of duloxetine (LY248686), a reuptake inhibitor of norepinephrine and serotonin, in mice and rats. J Pharmacol Exp Ther 1995 Mar; 272 (3): 1067-75
15. Iyengar S, Bymaster FP, Wong DT, et al. Efficacy of the selective serotonin and norepinephrine reuptake inhibitor, duloxetine, in the formalin model of persistent pain [abstract]. Pain Med 2002 Jun; 3 (2): 177
16. Turcotte JE, Debonnel G, de Montigny C, et al. Assessment of the serotonin and norepinephrine reuptake blocking properties of duloxetine in healthy subjects. Neuropsychopharmacology 2001 May; 24 (5): 511-21
17. Chalon SA, Granier LA, Vandenhende FR, et al. Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study. Neuropsychopharmacology 2003 Sep; 28 (9): 1685-93
18. Vincent S, Bieck PR, Garland EM, et al. Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles. Circulation 2004 Jun 29; 109 (25): 3202-7
19. Hunziker ME, Suehs BT, Bettinger TL, et al. Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder. Clin Ther 2005 Aug; 27 (8): 1126-43
20. Thase ME, Tran PV, Wiltse C, et al. Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine. J Clin Psychopharmacol 2005 Apr; 25 (2): 132-40
21. Chalon S, Bieck PR, Goldstein DJ, et al. The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition [letter]. Neuropsychopharmacology 2002; 26 (5): 698-701
22. Chalon S, Granier LA, Vandenhende F, et al. Duloxetine affects sleep architecture with antidepressant like pattern [abstract no. PII-65]. Clin Pharmacol Ther 2001 Feb; 69: P49
23. Kluge M, Schussler P, Steiger A. Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. Eur Neuropsychopharmacol 2007; 17 (8): 527-31
24. Sharma A, Goldberg MJ, Cerimele BJ. Pharmacokinetics and safety of duloxetine, a dual-serotonin and norepinephrine reuptake inhibitor. J Clin Pharmacol 2000 Feb; 40 (2): 161-7
25. Granier L-A, Vandenhende F, de Suray JM. Safety and pharmacokinetics of duloxetine, a potential new antidepressant with serotonin and norepinephrine uptake inhibition [abstract no. P.1.043]. Eur Neuropsychopharmacol 1999 Sep; 9 Suppl. 5: 222
26. Skinner MH, Skerjanec A, Seger M, et al. The effect of food and bedtime administration on duloxetine pharmacokinetics [abstract no. PII-59]. Clin Pharmacol Ther 2000 Feb; 67: 129
27. Lantz RJ, Gillespie TA, Rash TJ, et al. Metabolism, excretion, and pharmacokinetics of duloxetine in healthy human subjects. Drug Metab Dispos 2003 Sep; 31 (9): 1142-50
28. Suri A, Reddy S, Gonzales C, et al. Duloxetine pharmacokinetics in cirrhotics compared with healthy subjects. Int J Clin Pharmacol Ther 2005 Feb; 43 (2): 78-84
29. Kuo F, Gillespie TA, Kulanthaivel P, et al. Synthesis and biological activity of some known and putative duloxetine metabolites. Bioorg Med Chem Lett 2004 Jul 5; 14 (13): 3481-6
30. di Virgilio SN, Gonzales C, Knadler MP, et al. Effect of duloxetine on CYP1A2-mediated drug metabolism and the pharmacokinetics of theophylline [abstract no. TPII-78]. Clin Pharmacol Ther 2002 Feb; 71: 63
31. Skinner MH, Kuan HY, Pan A, et al. Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers. Clin Pharmacol Ther 2003 Mar; 73 (3): 170-7
32. Preskorn SH, Greenblatt DJ, Flockhart D, et al. Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers. J Clin Psychopharmacol 2007 Feb; 27 (1): 28-34
33. Skinner MH, Kuan HY, Skerjanec A, et al. Effect of age on the pharmacokinetics of duloxetine in women. Br J Clin Pharmacol 2004 Jan; 57 (1): 54-61
34. Chalon S, Vandenhende F, Ertle S. Combined administration of duloxetine and lorazepam: a pharmacokinetic and pharmacodynamic study [abstract no. PII-56]. Clin Pharmacol Ther 2005 Feb; 77 (2): 65
35. Skinner MH, Weerakkody G. Duloxetine does not exacerbate the effects of alcohol on psychometric tests [abstract no. TPII-45]. Clin Pharmacol Ther 2002 Feb; 71: 53
36. Glueck CJ, Khalil Q, Winiarska M, et al. Interaction of duloxetine and warfarin causing severe elevation of international normalized ratio. JAMA 2006 Apr 5; 295 (13): 1517-8
37. Chan C, Yeo KP, Pan AX, et al. Duloxetine pharmacokinetics are similar in Japanese and Caucasian subjects. Br J Clin Pharmacol 2007 Mar; 63 (3): 310-4
38. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine, 60mg once daily, for major depressive disorder: a randomized double-blind placebo-controlled trial. J Clin Psychiatry 2002 Apr; 63 (4): 308-15
39. Detke MJ, Lu Y, Goldstein DJ, et al. Duloxetine 60 mg once daily dosing versus placebo in the acute treatment of major depression. J Psychiatr Res 2002; 36 (6): 383-90
40. Goldstein DJ, Mallinckrodt C, Lu Y, et al. Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial. J Clin Psychiatry 2002 Mar; 63 (3): 225-31
41. Goldstein DJ, Lu Y, Detke MJ, et al. Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine. J Clin Psychopharmacol 2004 Aug; 24 (4): 389-99
42. Detke MJ, Wiltse CG, Mallinckrodt CH, et al. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Neuropsychopharmacol 2004 Dec; 14 (6): 457-70
43. Perahia DG, Wang F, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial. Eur Psychiatry 2006 May 10; 21 (6): 367-78
44. Brannan SK, Mallinckrodt CH, Brown EB, et al. Duloxetine 60mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder. J Psychiatr Res 2005 Jan; 39 (1): 43-53
45. Perahia DG, Gilaberte I, Wang F, et al. Duloxetine in the prevention of relapse of major depressive disorder. Br J Psychiatry 2006 Apr; 188: 346-53
46. Fava M, Detke MJ, Balestrieri M, et al. Management of depression relapse: re-initiation of duloxetine treatment or dose increase. J Psychiatr Res 2006 Jun; 40 (4): 328-36
47. Raskin J, Goldstein DJ, Mallinckrodt CH, et al. Duloxetine in the long-term treatment of major depressive disorder. J Clin Psychiatry 2003 Oct; 64 (10): 1237-44
48. Khan A, Bose A, Alexopoulos GS, et al. Double-blind comparison of escitalopram and duloxetine in the acute treatment of major depressive disorder. Clin Drug Invest 2007; 27 (7): 481-192
49. Nierenberg AA, Greist JH, Mallinckrodt CH, et al. Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study. Curr Med Res Opin 2007 Feb; 23 (2): 401-16
50. Wade A, Gembert K, Florea I, et al. A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder. Curr Med Res Opin 2007; 23 (7): 1605-14
51. Perahia DG, Pritchett YL, Kajdasz DK, et al. A randomized, double-blind comparison of duloxetine and venlafaxine in the treatment of patients with major depressive disorder [online]. J Psychiatr Res 2007 Apr 17. Available from URL: http://www.sciencedirect.com [Accessed 2007 10 Jun]
52. Raskin J, Wiltse CG, Siegal A, et al. Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder. Am J Psychiatry 2007; 164: 900-9
53. Brecht S, Courtecuisse C, Debieuvre C, et al. Efficacy of duloxetine in the treatment of unspecified pain associated with depression. 15th European Congress of Psychiatry; 2007 Mar 17-21; Madrid
54. Eli Lilly and Company. Clinical study summary: Study F1J-MC-HMAT Study Group A [online]. Available from URL: http://www.lillytrials.com/results_files/ cymbalta/cymbalta_summary_4091a.pdf [Accessed 2007 Jan 9]
55. Eli Lilly and Company. Clinical study summary: Study F1J-MC-HMAQ Study Group B [online]. Available from URL: http://www.lillytrials.com/results_files/ cymbalta/cymbalta_summary_3327b.pdf [Accessed 2007 Jan 9]
56. Nemeroff CB, Schatzberg AF, Goldstein DJ, et al. Duloxetine for the treatment of major depressive disorder. Psychopharmacol Bull 2002 Autumn; 36 (4): 106-32
57. Eli Lilly and Company clinical trial registry [online]. Available from URL: http://lillytrials.com/ [Accessed 2007 Jan 21]
58. Wise TN, Perahia DG, Pangallo BA, et al. Effects of the antidepressant duloxetine on body weight: analyses of 10 clinical studies. Prim Care Companion J Clin Psychiatry 2006; 8 (5): 269-78
59. Pigott TA, Arnold LM, Aaronson ST, et al. Duloxetine versus escitalopram and placebo in the long-term treatment of patients with MDD [abstract no. 13]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON), 73
60. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. Washington DC: American Psychiatric Association, 1994
61. Mallinckrodt CH, Raskin J, Wohlreich MM, et al. The efficacy of duloxetine: a comprehensive summary of results from MMRM and LOCF_ANCOVA in eight clinical trials. BMC Psychiatry 2004 Sep 8; 4 (26)
62. Mallinckrodt CH, Prakash A, Andorn AC, et al. Duloxetine for the treatment of major depressive disorder: a closer look at efficacy and safety data across the approved dose range. J Psychiatr Res 2006; 40: 337-48
63. Brannan SK, Mallinckrodt CH, Detke MJ, et al. Onset of action for duloxetine 60mg once daily: double-blind, placebo-controlled studies. J Psychiatr Res 2005 Mar; 39 (2): 161-72
64. Fava M, Mallinckrodt CH, Detke MJ, et al. The effect of duloxetine on painful physical symptoms in depressed patients: do improvements in these symptoms result in higher remission rates? J Clin Psychiatry 2004 Apr; 65 (4): 521-30
65. Perahia DG, Kajdasz DK, Royer MG, et al. Duloxetine in the treatment of major depressive disorder: an assessment of the relationship between outcomes and episode characteristics. Int Clin Psychopharmacol 2006 Sep; 21 (5): 285-95
66. Kornstein SG, Wohlreich M, Mallinckrodt CH, et al. Duloxetine efficacy for major depressive disorder in male vs. female patients: data from 7 randomized, double-blind, placebo-controlled trials. J Clin Psychiatry 2006; 67: 761-70
67. Mallinckrodt CH, Watkin JG, Liu C, et al. Duloxetine in the treatment of major depressive disorder: a comparison of efficacy in patients with and without melancholic features. BMC Psychiatry 2005; 5 (1)
68. Bech P, Kajdasz DK, Porsdal V. Dose-response relationship of duloxetine in placebo-controlled clinical trials in patients with major depressive disorder. Psychopharmacology (Berl) 2006 Oct; 188 (3): 273-80
69. Hirschfeld RMA, Mallinckrodt CH, Prakash A, et al. Efficacy of duloxetine versus combined SSRIs (fluoxetine, paroxetine, escitalopram) and placebo in the treatment of MDD [abstract no. 228 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON), 95
70. Prakash A, Potts A, Shelton R, et al. Efficacy of duloxetine vs. placebo in mild, moderate, and more severely ill patients with major depressive disorder [abstract no. NR270 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON)
71. Pum G. Efficacy of duloxetine versus placebo in mild, moderate, and more severely ill patients with major depressive disorder [abstract no. P38]. Int J Psychiatry Clin Pract 2006 Dec 1; 10 (4): 332
72. Pum G. Efficacy of duloxetine versus SSRIs and placebo in treating major depressive disorders [abstract no. P37]. Int J Psychiatry Clin Pract 2006 Dec 1; 10 (4): 331-2
73. Swindle RW, Mallinckrodt CH, Rosenbaum JF, et al. Efficacy of duloxetine treatment: analysis of pooled data from six placebo- and SSRI-controlled clinical trials [abstract no. NR722 plus poster]. 157th Annual Meeting of the American Psychiatric Association; 2004 May 1-5; New York (NY)
74. Andorn AC, Mallinckrodt C, Watkin J, et al. Efficacy of duloxetine in patients with mild, moderate, or severe depressive symptoms [abstract no. NR363 plus poster]. American Psychiatric Association 158th Annual Meeting; 2005 May 21-26; Atlanta (GA), 135
75. Thase ME, Lu Y, Joliat M, et al. Remission in placebo-controlled trials of duloxetine with an SSRI comparator [abstract no. 127]. Biol Psychiatry 2004; 55: 37S
76. McIntyre R, Kennedy S, Bagby RM, et al. Assessing full remission. J Psychiatry Neurosci 2002 Jul; 27 (4): 235-9
77. Ballesteros J, Callado LF, Gutierrez M. An independent meta-analysis using summary data for clinical response, remission, and discontinuation for any reason from the 6 pivotal phase III randomized clinical trials of duloxetine in major depressive disorder [letter]. J Clin Psychopharmacol 2007 Apr; 27 (2): 219-21
78. Wohlreich MM, Mallinckrodt CH, Watkin JG, et al. Duloxetine for the long-term treatment of major depressive disorder in patients aged 65 and older: an open-label study. BMC Geriatr 2004 Dec 7; 4 (11)
79. Gahimer J, Wernicke J, Yalcin I, et al. A retrospective pooled analysis of duloxetine safety in 23,983 subjects. Curr Med Res Opin 2007 Jan; 23 (1): 175-84
80. Hudson JI, Wohlreich MM, Kajdasz DK, et al. Safety and tolerability of duloxetine in the treatment of major depressive disorder: analysis of pooled data from eight placebo-controlled clinical trials. Hum Psychopharmacol 2005 Jul; 20 (5): 327-41
81. Dunner DL, Wohlreich MM, Mallinckrodt CH, et al. Clinical consequences of initial duloxetine dosing strategies: comparison of 30 and 60mg QD starting doses. Curr Ther Res Clin Exp 2005 Dec 1; 66 (6): 522-40
82. Wohlreich MM, Mallinckrodt CH, Prakash A, et al. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation. Depress Anxiety 2007; 24 (1): 41-52
83. Stewart DE, Wohlreich MM, Mallinckrodt CH, et al. Duloxetine in the treatment of major depressive disorder: comparisons of safety and tolerability in male and female patients. J Affect Disord 2006 Aug; 94 (1-3): 183-9
84. Perahia DG, Kajdasz DK, Desaiah D, et al. Symptoms following abrupt discontinuation of duloxetine treatment in patients with major depressive disorder. J Affect Disord 2005 Dec; 89 (1): 207-12
85. Zhang L, Chappell J, Gonzales CR, et al. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study. J Cardiovasc Pharmacol 2007 Mar; 49 (3): 146-53
86. Wernicke J, Lledo A, Raskin J, et al. An evaluation of the cardiovascular safety profile of duloxetine: findings from 42 placebo-controlled studies. Drug Saf 2007; 30 (5): 437-55
87. Acharya N, Rosen AS, Polzer JP, et al. Duloxetine: meta-analyses of suicidal behaviors and ideation in clinical trials for major depressive disorder. J Clin Psychopharmacol 2006 Dec; 26 (6): 587-94
88. Dunner DL, D'Souza DN, Kajdasz DK, et al. Is treatment-associated hypomania rare with duloxetine: secondary analysis of controlled trials in non-bipolar depression. J Affect Disord 2005 Jul; 87 (1): 115-9
89. Delgado PL, Brannan SK, Mallinckrodt CH, et al. Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder. J Clin Psychiatry 2005 Jun; 66 (6): 686-92
90. Nelson JC, Lu Pritchett Y, Martynov O, et al. The safety and tolerability of duloxetine compared with paroxetine and placebo: a pooled analysis of 4 clinical trials. Prim Care Companion J Clin Psychiatry 2006; 8 (4): 212-9
91. Greist J, McNamara RK, Mallinckrodt CH, et al. Incidence and duration of antidepressant-induced nausea: duloxetine compared with paroxetine and fluoxetine. Clin Ther 2004 Sep; 26 (9): 1446-55
92. Clayton A, Mallinckrodt CH, Wohlreich MM, et al. Sexual functioning in long-term treatment of MDD: duloxetine, escitalopram, and placebo [abstract no. NR199 plus poster]. 159th Annual Meeting of the American Psychiatric Association; 2006 May 20-25; Toronto (ON), 83
93. Kruger S, Lindstaedt M. Duloxetine and hyponatremia: a report of 5 cases [letter]. J Clin Psychopharmacol 2007 Feb; 27 (1): 101-4
94. Safdieh JE, Rudominer R. A case of hyponatremia induced by duloxetine [letter]. J Clin Psychopharmacol 2006 Dec; 26 (6): 675-6
95. Katon W, Schulberg H. Epidemiology of depression in primary care. Gen Hosp Psychiatry 1992 Jul; 14 (4): 237-47
96. Kessler RC, Berglund P, Demler O, et al. The epidemiology of major depressive disorder: results from National Comorbidity Survey Replication (NCS-R). JAMA 2003 Jun 18; 289 (23): 3095-105
97. Greden JF. The burden of disease for treatment-resistant depression. J Clin Psychiatry 2001; 62 Suppl. 16: 26-31
98. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997 May 24; 349 (9064): 1498-504
99. Ustun TB, Ayuso-Mateos JL, Chatterji S, et al. Global burden of depressive disorders in the year 2000. Br J Psychiatry 2004; 184: 386-92
100. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003 Dec; 64 (12): 1465-75
101. Gelenberg A, Merriam A, Karasu TB, et al. Practice guideline for the treatment of patients with major depressive disorder (revisions). American Psychiatric Association 2000; 157 (Suppl. 4): 1-45
102. National Institute for Clinical Excellence. NICE guidelines to improve the treatment and care of people with depression and anxiety [online]. Available from URL: http://www.nice.org.uk [Accessed 2007 Mar 12]
103. Kent JM. SNaRIs, NaSSAs, and NaRIs: new agents for the treatment of depression. Lancet 2000; 355: 911-8
104. Hansen RA, Gartlehner G, Lohr KN, et al. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005 Sep 20; 143 (6): 415-26
105. MacGillivray S, Arroll B, Hatcher S, et al. Efficacy and tolerability of selective serotonin reuptake inhibitors compared with tricyclic antidepressants in depression treated in primary care: systematic review and meta-analysis. BMJ 2003 May 10; 326 (7397): 1014
106. Westanmo AD, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrine- and serotonin-reuptake inhibitor. Am J Health Syst Pharm 2005 Dec 1; 62 (23): 2481-90
107. Kirwin JL, Goren JL. Duloxetine: an antidepressant that inhibits both norepinephrine and serotonin uptake. Formulary 2003; 38: 29-37
108. Lin EH, Von Korff M, Katon W, et al. The role of the primary care physician in patients' adherence to antidepressant therapy. Med Care 1995 Jan; 33 (1): 67-74
109. Khan A, Schwartz K. Study designs and outcomes in antidepressant clinical trials. Essent Psychopharmacol 2005; 6 (4): 221-6
110. Hirschfeld RM, Mallinckrodt C, Lee TC, et al. Time course of depression-symptom improvement during treatment with duloxetine. Depress Anxiety 2005; 21 (4): 170-7
111. Deakin B, Dursun S. Optimizing antidepressant treatment: efficacy and tolerability. Int Clin Psychopharmacol 2002; 17 Suppl. 1: S13-24
112. Machado M, Iskedjian M, Einarson T. Clinical comparison of SSRIs and SNRIs in major depressive disorder: a meta-analysis [abstract no. PMH43]. Value Health 2005 Dec; 8 ( 6): A209
113. Thase ME, Entsuah AR, Rudolph RL, et al. Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors. Br J Psychiatry 2001 Mar; 178: 234-41
114. Anderson IM. Meta-analytical studies on new antidepressants. Br Med Bull 2001; 57: 161-78
115. Hirschfeld RMA. The comorbidity of major depression and anxiety disorders: recognition and management in primary care. Primary Care Companion J Clin Psychiatry 2001; 3 (6): 244-54
116. Rouillon F. Anxiety with depression: a treatment need. Eur Neuropsychopharmacol 1999 Jul; 9 Suppl. 3: 87-92
117. Eli Lilly and Company. FDA approves Cymbalta® for treatment of generalized anxiety disorder [online]. Available from URL: http://newsroom. lilly.com [Accessed 2007 Mar 8]
118. Dunner DL, Goldstein DJ, Mallinckrodt CM, et al. Duloxetine in treatment of anxiety symptoms associated with depression. Depress Anxiety 2003; 18: 53-61
119. Perahia DG, Pritchett YL, Desaiah D, et al. Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect? Int Clin Psychopharmacol 2006 Nov; 21 (6): 311-7
120. Briley M. New hope in the treatment of painful symptoms in depression. Curr Opin Investig Drugs 2003 Jan; 4 (1): 42-5
121. Werneke U, Northey S, Bhugra D. Antidepressants and sexual dysfunction. Acta Psychiatr Scand 2006 Dec; 114 (6): 384-97
122. Garland EJ, Remick RA, Zip APS. Weight gain with antidepressants and lithium. J Clin Psychopharmacol 1988 Oct; 8 (5): 323-30
123. McIntyre RS, Soczynska JK, Konarski JZ, et al. The effect of antidepressants on lipid homeostasis: a cardiac safety concern? Expert Opin Drug Saf 2006 Jul; 5 (4): 523-37
124. van Baardewijk M, Vis PMJ, Einarson TR. Cost effectiveness of duloxetine compared with venlafaxine-XR in the treatment of major depressive disorder. Curr Med Res Opin 2005 Aug; 21 (8): 1271-9